ARVINAS INC (ARVN) Stock News

USA - Nasdaq - NASDAQ:ARVN - US04335A1051 - Common Stock

12.42 USD

+0.3 (+2.48%)

Last: 11/26/2025, 8:16:05 PM

12.49 USD

+0.07 (+0.56%)

After Hours: 11/26/2025, 8:16:05 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARVN Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Chartmill - Mentions: VNDA CMCT ZYXI OLMA ...

News Image

Top movers in Tuesday's session

9 days ago - By: Chartmill - Mentions: VNDA ENR UUU GSM ...

News Image

Let's uncover which stocks are experiencing notable gaps during today's session.

a day ago - By: Arvinas Inc.

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

a day ago - By: Arvinas Inc.

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

3 days ago - By: Arvinas Inc. - Mentions: PFE

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

3 days ago - By: Arvinas Inc.

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

9 days ago - By: Benzinga - Mentions: ZYXI ITRM OLMA LFMD ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

9 days ago - By: Chartmill - Mentions: MPAA ENR CANF OLLI ...

News Image

These stocks that are showing activity before the opening bell on Tuesday.

22 days ago - By: Zacks Investment Research - Mentions: TCRX

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

22 days ago - By: Arvinas Inc.

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

22 days ago - By: Arvinas Inc.

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

22 days ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

23 days ago - By: Zacks Investment Research - Mentions: VSTM

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates

24 days ago - By: Arvinas Inc.

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

24 days ago - By: Arvinas Inc.

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

24 days ago - By: Arvinas Inc.

Arvinas to Participate in Upcoming Investor Conferences

a month ago - By: Arvinas Inc.

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

a month ago - By: Arvinas Inc.

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

a month ago - By: Arvinas Inc.

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

a month ago - By: Zacks Investment Research - Mentions: ALNY

Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

a month ago - By: Arvinas Inc.

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

a month ago - By: Arvinas Inc.

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

a month ago - By: Arvinas Inc. - Mentions: PFE

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

a month ago - By: Arvinas Inc.

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

2 months ago - By: Arvinas Inc.

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

2 months ago - By: Arvinas Inc.

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

2 months ago - By: Arvinas Inc.

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

2 months ago - By: Arvinas Inc.

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

2 months ago - By: Arvinas Inc.

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

2 months ago - By: Arvinas Inc.

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

2 months ago - By: Arvinas Inc. - Mentions: PFE

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation